$FBIO
Fortress Biotech, Inc.

2022 Q2 Form 10-Q Financial Statement

#000155837022013275 Filed on August 11, 2022

View on sec.gov

Income Statement

Concept 2022 Q2 2021 Q4 2021 Q2
Revenue $18.89M $18.28M $17.84M
YoY Change 5.85% 32.92% 88.68%
Cost Of Revenue $7.633M $9.525M $7.484M
YoY Change 1.99% 122.55% 139.56%
Gross Profit $11.25M $8.751M $10.36M
YoY Change 8.63% -7.59% 63.57%
Gross Profit Margin 59.58% 47.88% 58.06%
Selling, General & Admin $29.05M $27.70M $19.38M
YoY Change 49.87% 75.19% 34.08%
% of Gross Profit 258.14% 316.51% 187.1%
Research & Development $33.13M $43.05M $33.83M
YoY Change -2.08% 139.72% 95.88%
% of Gross Profit 294.42% 491.99% 326.61%
Depreciation & Amortization $800.0K $1.251M $600.0K
YoY Change 33.33% 31.68% 0.0%
% of Gross Profit 7.11% 14.3% 5.79%
Operating Expenses $62.18M $70.75M $53.22M
YoY Change 16.84% 109.51% 67.72%
Operating Profit -$50.93M -$62.00M -$42.86M
YoY Change 18.83% 155.15% 68.75%
Interest Expense -$3.004M -$6.034M $26.16M
YoY Change -111.48% -252.76% 990.45%
% of Operating Profit
Other Income/Expense, Net -$3.004M $18.47M
YoY Change -116.27% -702.09%
Pretax Income -$53.93M -$68.04M -$50.46M
YoY Change 6.88% 234.32% 77.29%
Income Tax $0.00 $473.0K $0.00
% Of Pretax Income
Net Earnings -$21.36M -$31.57M -$3.535M
YoY Change 504.13% 495.57% -73.45%
Net Earnings / Revenue -113.08% -172.71% -19.81%
Basic Earnings Per Share -$0.24 -$0.04
Diluted Earnings Per Share -$0.24 -$377.4K -$0.04
COMMON SHARES
Basic Shares Outstanding 88.74M 80.96M
Diluted Shares Outstanding 88.74M 80.96M

Balance Sheet

Concept 2022 Q2 2021 Q4 2021 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $248.8M $305.7M $275.0M
YoY Change -9.54% 31.0% 50.02%
Cash & Equivalents $248.8M $305.7M $275.0M
Short-Term Investments
Other Short-Term Assets $5.120M $7.066M $4.003M
YoY Change 27.9% 5.46% 25.09%
Inventory $16.05M $9.862M $14.32M
Prepaid Expenses
Receivables $28.67M $23.11M $26.19M
Other Receivables $376.0K $678.0K $842.0K
Total Short-Term Assets $299.0M $346.5M $320.3M
YoY Change -6.67% 30.18% 60.33%
LONG-TERM ASSETS
Property, Plant & Equipment $14.02M $15.07M $13.13M
YoY Change 6.82% 26.36% 6.2%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $0.00 $48.48M
YoY Change -100.0% 336.79%
Other Assets $1.167M $1.198M $1.126M
YoY Change 3.64% 18.26% -16.59%
Total Long-Term Assets $64.96M $50.04M $97.81M
YoY Change -33.58% -25.6% 42.22%
TOTAL ASSETS
Total Short-Term Assets $299.0M $346.5M $320.3M
Total Long-Term Assets $64.96M $50.04M $97.81M
Total Assets $364.0M $396.5M $418.2M
YoY Change -12.96% 18.92% 55.7%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $53.94M $47.43M $14.27M
YoY Change 277.96% 315.61% -33.0%
Accrued Expenses $93.54M $90.66M $59.91M
YoY Change 56.14% 99.74% 183.4%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $7.487M $4.510M $3.861M
YoY Change 93.91% -14.91% -82.29%
Total Short-Term Liabilities $104.9M $101.0M $70.60M
YoY Change 48.61% 95.21% 23.93%
LONG-TERM LIABILITIES
Long-Term Debt $89.42M $46.56M $71.21M
YoY Change 25.58% -21.08% 2.45%
Other Long-Term Liabilities $1.940M $2.033M $1.856M
YoY Change 4.53% 4.31% -74.71%
Total Long-Term Liabilities $1.940M $2.033M $1.856M
YoY Change 4.53% 4.31% -74.71%
TOTAL LIABILITIES
Total Short-Term Liabilities $104.9M $101.0M $70.60M
Total Long-Term Liabilities $1.940M $2.033M $1.856M
Total Liabilities $216.3M $170.6M $169.9M
YoY Change 27.31% 25.08% 11.96%
SHAREHOLDERS EQUITY
Retained Earnings -$584.6M -$547.5M -$495.1M
YoY Change 18.07% 13.4% 7.19%
Common Stock $108.0K $101.0K $97.00K
YoY Change 11.34% 6.32% 12.79%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $77.22M $108.7M $108.3M
YoY Change
Total Liabilities & Shareholders Equity $364.0M $396.5M $418.2M
YoY Change -12.96% 18.92% 55.7%

Cashflow Statement

Concept 2022 Q2 2021 Q4 2021 Q2
OPERATING ACTIVITIES
Net Income -$21.36M -$31.57M -$3.535M
YoY Change 504.13% 495.57% -73.45%
Depreciation, Depletion And Amortization $800.0K $1.251M $600.0K
YoY Change 33.33% 31.68% 0.0%
Cash From Operating Activities -$41.42M -$38.70M -$34.46M
YoY Change 20.22% 88.95% 97.92%
INVESTING ACTIVITIES
Capital Expenditures -$307.0K -$1.957M -$2.690M
YoY Change -88.59% 117.44% -489.86%
Acquisitions
YoY Change
Other Investing Activities $0.00 $55.31M -$2.148M
YoY Change -100.0% -8355.22% 22.74%
Cash From Investing Activities -$307.0K $53.35M -$4.838M
YoY Change -93.65% -3520.06% 356.42%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.991M 38.94M 24.40M
YoY Change -87.74% 5.22% -62.93%
NET CHANGE
Cash From Operating Activities -41.42M -38.70M -34.46M
Cash From Investing Activities -307.0K 53.35M -4.838M
Cash From Financing Activities 2.991M 38.94M 24.40M
Net Change In Cash -38.74M 53.60M -14.90M
YoY Change 160.02% 258.04% -131.47%
FREE CASH FLOW
Cash From Operating Activities -$41.42M -$38.70M -$34.46M
Capital Expenditures -$307.0K -$1.957M -$2.690M
Free Cash Flow -$41.12M -$36.74M -$31.77M
YoY Change 29.43% 87.64% 75.51%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q2 fbio Earnings Per Share Including Portion Attributable To Noncontrolling Interest Diluted
EarningsPerShareIncludingPortionAttributableToNoncontrollingInterestDiluted
-0.61
CY2021Q2 fbio Earnings Per Share Including Portion Attributable To Noncontrolling Interest Diluted
EarningsPerShareIncludingPortionAttributableToNoncontrollingInterestDiluted
-0.30
fbio Earnings Per Share Including Portion Attributable To Noncontrolling Interest Diluted
EarningsPerShareIncludingPortionAttributableToNoncontrollingInterestDiluted
-1.18
fbio Earnings Per Share Including Portion Attributable To Noncontrolling Interest Diluted
EarningsPerShareIncludingPortionAttributableToNoncontrollingInterestDiluted
-0.62
CY2022Q2 fbio Earnings Per Share Attributable To Noncontrolling Interest Diluted
EarningsPerShareAttributableToNoncontrollingInterestDiluted
-0.37
CY2021Q2 fbio Earnings Per Share Attributable To Noncontrolling Interest Diluted
EarningsPerShareAttributableToNoncontrollingInterestDiluted
-0.26
fbio Earnings Per Share Attributable To Noncontrolling Interest Diluted
EarningsPerShareAttributableToNoncontrollingInterestDiluted
-0.76
fbio Earnings Per Share Attributable To Noncontrolling Interest Diluted
EarningsPerShareAttributableToNoncontrollingInterestDiluted
-0.47
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.24
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.04
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.42
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.15
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
88743457
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
80962994
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
87593952
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
80907671
dei Entity Central Index Key
EntityCentralIndexKey
0001429260
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021Q4 us-gaap Inventory Net
InventoryNet
9862000
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
dei Amendment Flag
AmendmentFlag
false
dei Entity Registrant Name
EntityRegistrantName
Fortress Biotech, Inc.
dei Entity Address State Or Province
EntityAddressStateOrProvince
FL
CY2022Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
3427138
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
3427138
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
107717647
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
101435505
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-35366
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-5157386
dei Entity Address Address Line1
EntityAddressAddressLine1
1111 Kane Concourse Suite 301
dei Entity Address City Or Town
EntityAddressCityOrTown
Bay Harbor Island
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
33154
dei City Area Code
CityAreaCode
781
dei Local Phone Number
LocalPhoneNumber
652-4500
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
248771000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
305744000
CY2022Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
28671000
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
23112000
CY2022Q2 us-gaap Inventory Net
InventoryNet
16053000
CY2022Q2 us-gaap Due From Other Related Parties Current
DueFromOtherRelatedPartiesCurrent
376000
CY2021Q4 us-gaap Due From Other Related Parties Current
DueFromOtherRelatedPartiesCurrent
678000
CY2022Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5120000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7066000
CY2022Q2 us-gaap Assets Current
AssetsCurrent
298991000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
346462000
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
14021000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
15066000
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
18116000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
19005000
CY2022Q2 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
2220000
CY2021Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
2220000
CY2022Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
29440000
CY2021Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
12552000
CY2022Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1167000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1198000
CY2022Q2 us-gaap Assets
Assets
363955000
CY2021Q4 us-gaap Assets
Assets
396503000
CY2022Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
93540000
CY2021Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
90660000
CY2022Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
1457000
CY2021Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
2611000
CY2022Q2 us-gaap Taxes Payable Current
TaxesPayableCurrent
345000
CY2021Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
345000
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2092000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2104000
CY2022Q2 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
0
CY2021Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
812000
CY2022Q2 fbio Partner Company Installment Payments Licenses Current
PartnerCompanyInstallmentPaymentsLicensesCurrent
7487000
CY2021Q4 fbio Partner Company Installment Payments Licenses Current
PartnerCompanyInstallmentPaymentsLicensesCurrent
4510000
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
104921000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
101042000
CY2022Q2 us-gaap Long Term Notes Payable
LongTermNotesPayable
85611000
CY2021Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
42937000
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
19973000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
20987000
CY2022Q2 fbio Partner Company Installment Payments Licenses Noncurrent
PartnerCompanyInstallmentPaymentsLicensesNoncurrent
3808000
CY2021Q4 fbio Partner Company Installment Payments Licenses Noncurrent
PartnerCompanyInstallmentPaymentsLicensesNoncurrent
3627000
CY2022Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1940000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2033000
CY2022Q2 us-gaap Liabilities
Liabilities
216253000
CY2021Q4 us-gaap Liabilities
Liabilities
170626000
CY2022Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
15000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
15000000
CY2022Q2 fbio Preferred Stock Shares Designated
PreferredStockSharesDesignated
5000000
CY2021Q4 fbio Preferred Stock Shares Designated
PreferredStockSharesDesignated
5000000
CY2022Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
3427138
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
3427138
CY2022Q2 us-gaap Preferred Stock Liquidation Preference
PreferredStockLiquidationPreference
25.00
CY2021Q4 us-gaap Preferred Stock Liquidation Preference
PreferredStockLiquidationPreference
25.00
CY2022Q2 us-gaap Preferred Stock Value
PreferredStockValue
3000
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
3000
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
107717647
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
170000000
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
101435505
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
108000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
101000
CY2022Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
661691000
CY2021Q2 us-gaap Revenues
Revenues
17843000
us-gaap Revenues
Revenues
42811000
us-gaap Revenues
Revenues
29430000
CY2022Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
7633000
CY2021Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
7484000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
15836000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
11392000
CY2022Q2 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
33130000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
656033000
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-584579000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-547463000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
77223000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
108674000
CY2022Q2 us-gaap Minority Interest
MinorityInterest
70479000
CY2021Q4 us-gaap Minority Interest
MinorityInterest
117203000
CY2022Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
147702000
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
225877000
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
363955000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
396503000
CY2022Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
18235000
CY2021Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
15288000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
39031000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
26007000
CY2022Q2 fbio Collaboration Revenue
CollaborationRevenue
577000
CY2021Q2 fbio Collaboration Revenue
CollaborationRevenue
2400000
fbio Collaboration Revenue
CollaborationRevenue
1154000
fbio Collaboration Revenue
CollaborationRevenue
3200000
CY2022Q2 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
18000
CY2021Q2 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
155000
us-gaap Revenue From Related Parties
RevenueFromRelatedParties
70000
us-gaap Revenue From Related Parties
RevenueFromRelatedParties
223000
CY2022Q2 us-gaap Other Income
OtherIncome
56000
us-gaap Other Income
OtherIncome
2556000
CY2022Q2 us-gaap Revenues
Revenues
18886000
CY2021Q2 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
22831000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
69852000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
42859000
CY2022Q2 us-gaap Research And Development Asset Acquired Other Than Through Business Combination Written Off
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
1000
CY2021Q2 us-gaap Research And Development Asset Acquired Other Than Through Business Combination Written Off
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
11003000
us-gaap Research And Development Asset Acquired Other Than Through Business Combination Written Off
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
1000
us-gaap Research And Development Asset Acquired Other Than Through Business Combination Written Off
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
11129000
CY2022Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
29048000
CY2021Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
19382000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
55318000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
36924000
CY2022Q2 us-gaap Costs And Expenses
CostsAndExpenses
69812000
CY2021Q2 us-gaap Costs And Expenses
CostsAndExpenses
60700000
us-gaap Costs And Expenses
CostsAndExpenses
141007000
us-gaap Costs And Expenses
CostsAndExpenses
102304000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-50926000
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-42857000
us-gaap Operating Income Loss
OperatingIncomeLoss
-98196000
us-gaap Operating Income Loss
OperatingIncomeLoss
-72874000
CY2022Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
150000
CY2021Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
146000
us-gaap Investment Income Interest
InvestmentIncomeInterest
292000
us-gaap Investment Income Interest
InvestmentIncomeInterest
373000
CY2022Q2 fbio Interest Expense And Finance Fees
InterestExpenseAndFinanceFees
3154000
CY2021Q2 fbio Interest Expense And Finance Fees
InterestExpenseAndFinanceFees
2760000
fbio Interest Expense And Finance Fees
InterestExpenseAndFinanceFees
5504000
fbio Interest Expense And Finance Fees
InterestExpenseAndFinanceFees
4949000
CY2021Q2 fbio Change In Fair Value Of Short Term Investments
ChangeInFairValueOfShortTermInvestments
25005000
fbio Change In Fair Value Of Short Term Investments
ChangeInFairValueOfShortTermInvestments
30918000
CY2021Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
3925000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
3925000
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-3004000
CY2021Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
18466000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-5212000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
22417000
CY2022Q2 us-gaap Profit Loss
ProfitLoss
-53930000
CY2021Q2 us-gaap Profit Loss
ProfitLoss
-24391000
us-gaap Profit Loss
ProfitLoss
-103408000
us-gaap Profit Loss
ProfitLoss
-50457000
CY2022Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-32574000
CY2021Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-20856000
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-66292000
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-38100000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-21356000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-3535000
us-gaap Net Income Loss
NetIncomeLoss
-37116000
us-gaap Net Income Loss
NetIncomeLoss
-12357000
CY2022Q2 fbio Earnings Per Share Including Portion Attributable To Noncontrolling Interest Basic
EarningsPerShareIncludingPortionAttributableToNoncontrollingInterestBasic
-0.61
CY2021Q2 fbio Earnings Per Share Including Portion Attributable To Noncontrolling Interest Basic
EarningsPerShareIncludingPortionAttributableToNoncontrollingInterestBasic
-0.30
fbio Earnings Per Share Including Portion Attributable To Noncontrolling Interest Basic
EarningsPerShareIncludingPortionAttributableToNoncontrollingInterestBasic
-1.18
fbio Earnings Per Share Including Portion Attributable To Noncontrolling Interest Basic
EarningsPerShareIncludingPortionAttributableToNoncontrollingInterestBasic
-0.62
CY2022Q2 fbio Earnings Per Share Attributable To Noncontrolling Interest Basic
EarningsPerShareAttributableToNoncontrollingInterestBasic
-0.37
CY2021Q2 fbio Earnings Per Share Attributable To Noncontrolling Interest Basic
EarningsPerShareAttributableToNoncontrollingInterestBasic
-0.26
fbio Earnings Per Share Attributable To Noncontrolling Interest Basic
EarningsPerShareAttributableToNoncontrollingInterestBasic
-0.76
fbio Earnings Per Share Attributable To Noncontrolling Interest Basic
EarningsPerShareAttributableToNoncontrollingInterestBasic
-0.47
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.24
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.04
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.42
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.15
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
88743457
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
80962994
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
87593952
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
80907671
CY2022Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
193578000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
5081000
CY2022Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
99000
CY2022Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
147702000
CY2021Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
244225000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
4350000
CY2021Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
137000
CY2021Q2 us-gaap Dividends Preferred Stock
DividendsPreferredStock
2008000
CY2021Q2 fbio Adjustments To Additional Paid In Capital Subsidiary At Market Offering
AdjustmentsToAdditionalPaidInCapitalSubsidiaryAtMarketOffering
25910000
CY2021Q2 us-gaap Dividends Common Stock
DividendsCommonStock
188000
CY2021Q2 fbio Adjustments To Additional Paid In Capital Stock Issued For Research And Development Expenses
AdjustmentsToAdditionalPaidInCapitalStockIssuedForResearchAndDevelopmentExpenses
3000
CY2021Q2 fbio Common Shares Issuable For Dividend On Partner Company Convertible Preferred Shares
CommonSharesIssuableForDividendOnPartnerCompanyConvertiblePreferredShares
263000
CY2021Q2 us-gaap Net Income Loss Attributable To Nonredeemable Noncontrolling Interest
NetIncomeLossAttributableToNonredeemableNoncontrollingInterest
20856000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-3535000
CY2022Q2 fbio Issuance Of Common Stock For At Market Offering
IssuanceOfCommonStockForAtMarketOffering
1301000
CY2022Q2 us-gaap Dividends Preferred Stock
DividendsPreferredStock
2008000
CY2022Q2 fbio Adjustments To Additional Paid In Capital Subsidiary At Market Offering
AdjustmentsToAdditionalPaidInCapitalSubsidiaryAtMarketOffering
3693000
CY2022Q2 us-gaap Dividends Common Stock
DividendsCommonStock
188000
CY2022Q2 fbio Adjustments To Additional Paid In Capital Stock Issued For Research And Development Expenses
AdjustmentsToAdditionalPaidInCapitalStockIssuedForResearchAndDevelopmentExpenses
-35000
CY2022Q2 fbio Partner Companys Exercise Of Options For Cash
PartnerCompanysExerciseOfOptionsForCash
111000
CY2022Q2 us-gaap Net Income Loss Attributable To Nonredeemable Noncontrolling Interest
NetIncomeLossAttributableToNonredeemableNoncontrollingInterest
32574000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-21356000
CY2021Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
248301000
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
225877000
us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
10644000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
99000
fbio Issuance Of Common Stock For At Market Offering
IssuanceOfCommonStockForAtMarketOffering
5527000
us-gaap Dividends Preferred Stock
DividendsPreferredStock
4016000
fbio Adjustments To Additional Paid In Capital Subsidiary At Market Offering
AdjustmentsToAdditionalPaidInCapitalSubsidiaryAtMarketOffering
14476000
fbio Partner Companys Exercise Of Options For Cash
PartnerCompanysExerciseOfOptionsForCash
111000
fbio Issuance Of Common Stock Under Partner Companys Employee Stock Purchase Program
IssuanceOfCommonStockUnderPartnerCompanysEmployeeStockPurchaseProgram
116000
us-gaap Dividends Common Stock
DividendsCommonStock
375000
fbio Settlement Of Shares Withheld For Taxes
SettlementOfSharesWithheldForTaxes
1698000
fbio Adjustments To Additional Paid In Capital Stock Issued For Research And Development Expenses
AdjustmentsToAdditionalPaidInCapitalStockIssuedForResearchAndDevelopmentExpenses
-35000
fbio Stock Issued During Period Value Cash Less Exercise Of Warrants
StockIssuedDuringPeriodValueCashLessExerciseOfWarrants
384000
us-gaap Net Income Loss Attributable To Nonredeemable Noncontrolling Interest
NetIncomeLossAttributableToNonredeemableNoncontrollingInterest
66292000
us-gaap Net Income Loss
NetIncomeLoss
-37116000
CY2022Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
147702000
CY2020Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
196999000
us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
8123000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
137000
us-gaap Dividends Preferred Stock
DividendsPreferredStock
4015000
fbio Adjustments To Additional Paid In Capital Subsidiary At Market Offering
AdjustmentsToAdditionalPaidInCapitalSubsidiaryAtMarketOffering
97332000
fbio Partner Companys Exercise Of Options For Cash
PartnerCompanysExerciseOfOptionsForCash
7000
fbio Issuance Of Common Stock Under Partner Companys Employee Stock Purchase Program
IssuanceOfCommonStockUnderPartnerCompanysEmployeeStockPurchaseProgram
158000
us-gaap Dividends Common Stock
DividendsCommonStock
375000
fbio Adjustments To Additional Paid In Capital Stock Issued For Research And Development Expenses
AdjustmentsToAdditionalPaidInCapitalStockIssuedForResearchAndDevelopmentExpenses
129000
fbio Common Shares Issuable For Dividend On Partner Company Convertible Preferred Shares
CommonSharesIssuableForDividendOnPartnerCompanyConvertiblePreferredShares
263000
us-gaap Net Income Loss Attributable To Nonredeemable Noncontrolling Interest
NetIncomeLossAttributableToNonredeemableNoncontrollingInterest
38100000
us-gaap Net Income Loss
NetIncomeLoss
-12357000
CY2021Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
248301000
us-gaap Profit Loss
ProfitLoss
-103408000
us-gaap Profit Loss
ProfitLoss
-50457000
us-gaap Depreciation
Depreciation
1495000
us-gaap Depreciation
Depreciation
1212000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-239000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-45000
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-57000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
946000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
903000
us-gaap Paid In Kind Interest
PaidInKindInterest
418000
us-gaap Paid In Kind Interest
PaidInKindInterest
441000
us-gaap Cost Of Goods And Services Sold Amortization
CostOfGoodsAndServicesSoldAmortization
2034000
us-gaap Cost Of Goods And Services Sold Amortization
CostOfGoodsAndServicesSoldAmortization
1325000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
889000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
837000
us-gaap Share Based Compensation
ShareBasedCompensation
10644000
us-gaap Share Based Compensation
ShareBasedCompensation
8123000
fbio Issuance Of Common Stock For Research And Development Expenses
IssuanceOfCommonStockForResearchAndDevelopmentExpenses
-35000
fbio Issuance Of Common Stock For Research And Development Expenses
IssuanceOfCommonStockForResearchAndDevelopmentExpenses
129000
fbio Partner Company Warrant Expense Issued In Conjunction With Debt
PartnerCompanyWarrantExpenseIssuedInConjunctionWithDebt
0
fbio Partner Company Warrant Expense Issued In Conjunction With Debt
PartnerCompanyWarrantExpenseIssuedInConjunctionWithDebt
263000
fbio Change In Fair Value Of Short Term Investments
ChangeInFairValueOfShortTermInvestments
0
fbio Change In Fair Value Of Short Term Investments
ChangeInFairValueOfShortTermInvestments
30918000
fbio Change In Fair Value Of Contingently Issuable Warrants
ChangeInFairValueOfContingentlyIssuableWarrants
0
fbio Change In Fair Value Of Contingently Issuable Warrants
ChangeInFairValueOfContingentlyIssuableWarrants
3925000
fbio Research And Development Licenses Acquired Expense
ResearchAndDevelopmentLicensesAcquiredExpense
0
fbio Research And Development Licenses Acquired Expense
ResearchAndDevelopmentLicensesAcquiredExpense
11000000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
5514000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
2208000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
150000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
12911000
us-gaap Increase Decrease Due From Other Related Parties
IncreaseDecreaseDueFromOtherRelatedParties
-302000
us-gaap Increase Decrease Due From Other Related Parties
IncreaseDecreaseDueFromOtherRelatedParties
98000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1946000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2795000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-31000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
113000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
4197000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
5834000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-1154000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
4800000
fbio Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
-1026000
fbio Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
-880000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-93000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-93000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-88284000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-56148000
us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
0
us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
2750000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1644000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2148000
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
0
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
400000
fbio Proceeds From Sale Payments For Acquisition Of Vyne Products
ProceedsFromSalePaymentsForAcquisitionOfVyneProducts
-20000000
fbio Proceeds From Sale Payments For Acquisition Of Vyne Products
ProceedsFromSalePaymentsForAcquisitionOfVyneProducts
0
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-21644000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-5298000
us-gaap Payments Of Dividends Preferred Stock And Preference Stock
PaymentsOfDividendsPreferredStockAndPreferenceStock
4016000
us-gaap Payments Of Dividends Preferred Stock And Preference Stock
PaymentsOfDividendsPreferredStockAndPreferenceStock
4015000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
5527000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
99000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
137000
fbio Proceeds From Subsidiary S Employee Stock Purchase Plan
ProceedsFromSubsidiarySEmployeeStockPurchasePlan
116000
fbio Proceeds From Subsidiary S Employee Stock Purchase Plan
ProceedsFromSubsidiarySEmployeeStockPurchasePlan
158000
us-gaap Payments Of Dividends Common Stock
PaymentsOfDividendsCommonStock
375000
us-gaap Payments Of Dividends Common Stock
PaymentsOfDividendsCommonStock
375000
fbio Payment Of Costs Related To Partner Companies Sale Of Stock
PaymentOfCostsRelatedToPartnerCompaniesSaleOfStock
371000
fbio Payment Of Costs Related To Partner Companies Sale Of Stock
PaymentOfCostsRelatedToPartnerCompaniesSaleOfStock
0
fbio Proceeds From Issuance Of Subsidiaries At Market Offering
ProceedsFromIssuanceOfSubsidiariesAtMarketOffering
14476000
fbio Proceeds From Issuance Of Subsidiaries At Market Offering
ProceedsFromIssuanceOfSubsidiariesAtMarketOffering
97248000
fbio Proceeds From Partner Company Share Settled Notes
ProceedsFromPartnerCompanyShareSettledNotes
0
fbio Proceeds From Partner Company Share Settled Notes
ProceedsFromPartnerCompanyShareSettledNotes
12800000
fbio Proceeds From Exercise Of Equity Grants
ProceedsFromExerciseOfEquityGrants
111000
fbio Proceeds From Exercise Of Equity Grants
ProceedsFromExerciseOfEquityGrants
7000
fbio Proceeds From Payments For Settlement Of Shares Withheld For Taxes
ProceedsFromPaymentsForSettlementOfSharesWithheldForTaxes
-1698000
fbio Proceeds From Payments For Settlement Of Shares Withheld For Taxes
ProceedsFromPaymentsForSettlementOfSharesWithheldForTaxes
0
fbio Proceeds From Payments For Debt Issuance Costs Related To Oaktree Note
ProceedsFromPaymentsForDebtIssuanceCostsRelatedToOaktreeNote
0
fbio Proceeds From Payments For Debt Issuance Costs Related To Oaktree Note
ProceedsFromPaymentsForDebtIssuanceCostsRelatedToOaktreeNote
-60000
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
2000000
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
2800000
fbio Payment Of Debt Issuance Costs Associated With Partner Company Share Settled Notes
PaymentOfDebtIssuanceCostsAssociatedWithPartnerCompanyShareSettledNotes
214000
fbio Payment Of Debt Issuance Costs Associated With Partner Company Share Settled Notes
PaymentOfDebtIssuanceCostsAssociatedWithPartnerCompanyShareSettledNotes
13000
us-gaap Proceeds From Long Term Lines Of Credit
ProceedsFromLongTermLinesOfCredit
42112000
us-gaap Proceeds From Long Term Lines Of Credit
ProceedsFromLongTermLinesOfCredit
0
us-gaap Repayments Of Long Term Lines Of Credit
RepaymentsOfLongTermLinesOfCredit
812000
us-gaap Repayments Of Long Term Lines Of Credit
RepaymentsOfLongTermLinesOfCredit
0
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
52955000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
103087000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-56973000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
41641000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
307964000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
234996000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
250991000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
276637000
us-gaap Interest Paid Net
InterestPaidNet
3987000
us-gaap Interest Paid Net
InterestPaidNet
3339000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
166000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
504000
fbio Settlement Of Restricted Shares Units Into Common Stock
SettlementOfRestrictedSharesUnitsIntoCommonStock
3000
fbio Settlement Of Restricted Shares Units Into Common Stock
SettlementOfRestrictedSharesUnitsIntoCommonStock
2000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
315000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
298000
fbio Unpaid Partner Company Intangible Assets
UnpaidPartnerCompanyIntangibleAssets
4740000
fbio Unpaid Partner Company Intangible Assets
UnpaidPartnerCompanyIntangibleAssets
0
fbio Unpaid Partner Companys Debt Offering Cost
UnpaidPartnerCompanysDebtOfferingCost
1050000
fbio Unpaid Partner Companys Debt Offering Cost
UnpaidPartnerCompanysDebtOfferingCost
200000
fbio Unpaid Partner Companys Deferred Offering Cost
UnpaidPartnerCompanysDeferredOfferingCost
0
fbio Unpaid Partner Companys Deferred Offering Cost
UnpaidPartnerCompanysDeferredOfferingCost
75000
fbio Partner Company Derivative Warrant Liability Associated With Partner Company Share Settled Notes
PartnerCompanyDerivativeWarrantLiabilityAssociatedWithPartnerCompanyShareSettledNotes
0
fbio Partner Company Derivative Warrant Liability Associated With Partner Company Share Settled Notes
PartnerCompanyDerivativeWarrantLiabilityAssociatedWithPartnerCompanyShareSettledNotes
362000
fbio Conversion Of Partner Company Convertible Preferred Shares
ConversionOfPartnerCompanyConvertiblePreferredShares
384000
fbio Conversion Of Partner Company Convertible Preferred Shares
ConversionOfPartnerCompanyConvertiblePreferredShares
0
fbio Unpaid Research And Development License Acquired
UnpaidResearchAndDevelopmentLicenseAcquired
0
fbio Unpaid Research And Development License Acquired
UnpaidResearchAndDevelopmentLicenseAcquired
8250000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
81000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company’s unaudited condensed consolidated financial statements include certain amounts that are based on management’s best estimates and judgments. The Company’s significant estimates include, but are not limited to, useful lives assigned to long-lived assets, fair value of stock options and warrants, stock-based compensation, common stock issued to acquire licenses, investments, accrued expenses, provisions for income taxes, and contingencies. Due to the uncertainty inherent in such estimates, actual results may differ from these estimates.</p>
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
248771000
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
274992000
CY2022Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
2220000
CY2021Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1645000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
250991000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
276637000
CY2022Q2 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
7208000
CY2021Q4 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
5572000
CY2022Q2 us-gaap Inventory Work In Process
InventoryWorkInProcess
2662000
CY2022Q2 us-gaap Inventory Finished Goods
InventoryFinishedGoods
6242000
CY2021Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
4290000
CY2022Q2 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
59000
CY2022Q2 us-gaap Inventory Net
InventoryNet
16053000
CY2021Q4 us-gaap Inventory Net
InventoryNet
9862000
CY2022Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
24910000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
24460000
CY2022Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
10889000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
9394000
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
14021000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
15066000
CY2022Q2 us-gaap Depreciation
Depreciation
800000
CY2021Q2 us-gaap Depreciation
Depreciation
600000
us-gaap Depreciation
Depreciation
1500000
us-gaap Depreciation
Depreciation
1200000
CY2022Q2 fbio Imputed Interest Related To Partner Company Installment Payments Licenses
ImputedInterestRelatedToPartnerCompanyInstallmentPaymentsLicenses
705000
CY2022Q2 fbio Partner Company Installment Payments Licenses Current
PartnerCompanyInstallmentPaymentsLicensesCurrent
7487000
CY2022Q2 fbio Partner Company Installment Payments Licenses Noncurrent
PartnerCompanyInstallmentPaymentsLicensesNoncurrent
3808000
CY2022Q2 fbio Partner Company Installment Payments Licenses
PartnerCompanyInstallmentPaymentsLicenses
11295000
CY2022Q2 us-gaap Interest Expense Debt
InterestExpenseDebt
3154000
CY2021Q2 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
2166000
CY2021Q2 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
594000
CY2022Q2 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
10439000
CY2021Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
7063000
CY2021Q4 fbio Decrease In Note Payable
DecreaseInNotePayable
10450000
CY2022Q2 us-gaap Long Term Debt
LongTermDebt
85611000
CY2021Q4 us-gaap Long Term Debt
LongTermDebt
42937000
CY2022Q2 fbio Partner Company Installment Payments Licenses Current Gross
PartnerCompanyInstallmentPaymentsLicensesCurrentGross
8000000
CY2022Q2 fbio Partner Company Installment Payments Licenses Noncurrent Gross
PartnerCompanyInstallmentPaymentsLicensesNoncurrentGross
4000000
CY2022Q2 fbio Parner Company Installment Payments Licenses Gross
ParnerCompanyInstallmentPaymentsLicensesGross
12000000
CY2022Q2 fbio Imputed Interest Related To Partner Company Installment Payments Licenses Current
ImputedInterestRelatedToPartnerCompanyInstallmentPaymentsLicensesCurrent
513000
CY2022Q2 fbio Imputed Interest Related To Partner Company Installment Payments Licenses Noncurrent
ImputedInterestRelatedToPartnerCompanyInstallmentPaymentsLicensesNoncurrent
192000
CY2021Q4 fbio Partner Company Installment Payments Licenses Current Gross
PartnerCompanyInstallmentPaymentsLicensesCurrentGross
5000000
CY2021Q4 fbio Partner Company Installment Payments Licenses Noncurrent Gross
PartnerCompanyInstallmentPaymentsLicensesNoncurrentGross
4000000
CY2021Q4 fbio Parner Company Installment Payments Licenses Gross
ParnerCompanyInstallmentPaymentsLicensesGross
9000000
CY2021Q4 fbio Imputed Interest Related To Partner Company Installment Payments Licenses Current
ImputedInterestRelatedToPartnerCompanyInstallmentPaymentsLicensesCurrent
490000
CY2021Q4 fbio Imputed Interest Related To Partner Company Installment Payments Licenses Noncurrent
ImputedInterestRelatedToPartnerCompanyInstallmentPaymentsLicensesNoncurrent
373000
CY2021Q4 fbio Imputed Interest Related To Partner Company Installment Payments Licenses
ImputedInterestRelatedToPartnerCompanyInstallmentPaymentsLicenses
863000
CY2021Q4 fbio Partner Company Installment Payments Licenses Current
PartnerCompanyInstallmentPaymentsLicensesCurrent
4510000
CY2021Q4 fbio Partner Company Installment Payments Licenses Noncurrent
PartnerCompanyInstallmentPaymentsLicensesNoncurrent
3627000
CY2021Q4 fbio Partner Company Installment Payments Licenses
PartnerCompanyInstallmentPaymentsLicenses
8137000
CY2022Q2 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
2597000
CY2022Q2 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
557000
CY2021Q2 us-gaap Interest Expense Debt
InterestExpenseDebt
2760000
us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
4558000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
946000
us-gaap Interest Expense Debt
InterestExpenseDebt
5504000
us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
4046000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
903000
us-gaap Interest Expense Debt
InterestExpenseDebt
4949000
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
53939000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
47429000
CY2022Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1796000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1835000
CY2022Q2 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
7510000
CY2021Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
8809000
CY2022Q2 fbio Accrued Research And Development Expense
AccruedResearchAndDevelopmentExpense
8736000
CY2021Q4 fbio Accrued Research And Development Expense
AccruedResearchAndDevelopmentExpense
7932000
CY2022Q2 fbio Accrued Research And Development Expense License Maintenance Fees
AccruedResearchAndDevelopmentExpenseLicenseMaintenanceFees
502000
CY2021Q4 fbio Accrued Research And Development Expense License Maintenance Fees
AccruedResearchAndDevelopmentExpenseLicenseMaintenanceFees
4640000
CY2022Q2 fbio Accrued Research And Development Expense Milestones
AccruedResearchAndDevelopmentExpenseMilestones
4600000
CY2021Q4 fbio Accrued Research And Development Expense Milestones
AccruedResearchAndDevelopmentExpenseMilestones
850000
CY2022Q2 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
3027000
CY2021Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
3833000
CY2022Q2 fbio Accrued Coupon Expense Current
AccruedCouponExpenseCurrent
8205000
CY2021Q4 fbio Accrued Coupon Expense Current
AccruedCouponExpenseCurrent
10603000
CY2022Q2 fbio Accrued Return Reserve Current
AccruedReturnReserveCurrent
2727000
CY2021Q4 fbio Accrued Return Reserve Current
AccruedReturnReserveCurrent
3240000
CY2022Q2 us-gaap Interest Payable Current And Noncurrent
InterestPayableCurrentAndNoncurrent
204000
CY2021Q4 us-gaap Interest Payable Current And Noncurrent
InterestPayableCurrentAndNoncurrent
0
CY2022Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2294000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1489000
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
93540000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
90660000
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-66292000
CY2022Q2 us-gaap Minority Interest
MinorityInterest
70479000
CY2021 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-100123000
CY2021Q4 us-gaap Minority Interest
MinorityInterest
117203000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
315000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
6.36
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
705990
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
4.44
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P1Y10M28D
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
705990
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
4.44
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P1Y10M28D
CY2022Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
0
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
24012169
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
21955984
CY2022Q2 fbio Common Stock Increase Decrease In Shares Authorized
CommonStockIncreaseDecreaseInSharesAuthorized
30000000
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5081000
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4350000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10644000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8123000
fbio Class Of Warrant Or Right Exercisable Weighted Average Exercise Price
ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice
3.23
fbio Class Of Warrant Or Right Exercisable Weighted Average Intrinsic Value
ClassOfWarrantOrRightExercisableWeightedAverageIntrinsicValue
0
fbio Class Of Warrant Or Right Exercisable Weighted Average Remaining Contractual Life
ClassOfWarrantOrRightExercisableWeightedAverageRemainingContractualLife
P3Y4M17D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
1018490
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
5.04
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
368344
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P1Y8M4D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2500
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.50
fbio Share Based Compensation Arrangement Options Granted Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementOptionsGrantedWeightedAverageRemainingContractualTerm
P9Y6M3D
CY2021Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
4505621
CY2021Q4 fbio Class Of Warrant Or Right Weighted Average Exercise Price
ClassOfWarrantOrRightWeightedAverageExercisePrice
3.20
CY2021Q4 fbio Class Of Warrant Or Right Weighted Average Intrinsic Value
ClassOfWarrantOrRightWeightedAverageIntrinsicValue
68800
CY2021 fbio Class Of Warrant Or Right Weighted Average Remaining Contractual Life
ClassOfWarrantOrRightWeightedAverageRemainingContractualLife
P3Y11M4D
fbio Class Of Warrant Or Right Number Of Shares Expired
ClassOfWarrantOrRightNumberOfSharesExpired
508505
fbio Class Of Warrant Or Right Expired Weighted Average Exercise Price
ClassOfWarrantOrRightExpiredWeightedAverageExercisePrice
3.73
CY2022Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
3997116
CY2022Q2 fbio Class Of Warrant Or Right Weighted Average Exercise Price
ClassOfWarrantOrRightWeightedAverageExercisePrice
3.13
CY2022Q2 fbio Class Of Warrant Or Right Weighted Average Intrinsic Value
ClassOfWarrantOrRightWeightedAverageIntrinsicValue
0
fbio Class Of Warrant Or Right Weighted Average Remaining Contractual Life
ClassOfWarrantOrRightWeightedAverageRemainingContractualLife
P3Y10M20D
fbio Class Of Warrant Or Right Exercisable
ClassOfWarrantOrRightExercisable
4370621
fbio Annual Management Services Agreement Fee Income
AnnualManagementServicesAgreementFeeIncome
5000000
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2
CY2022Q2 us-gaap Revenues
Revenues
18886000
CY2022Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
7633000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
33131000
CY2022Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
29048000
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-3004000
CY2022Q2 us-gaap Profit Loss
ProfitLoss
-53930000
CY2021Q2 us-gaap Revenues
Revenues
17843000
CY2021Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
7484000
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
33834000
CY2021Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
19382000
CY2021Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
18466000
CY2021Q2 us-gaap Profit Loss
ProfitLoss
-24391000
us-gaap Revenues
Revenues
42811000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
15836000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
69853000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
55318000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-5212000
us-gaap Profit Loss
ProfitLoss
-103408000
us-gaap Revenues
Revenues
29430000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
11392000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
53988000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
36924000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
22417000
us-gaap Profit Loss
ProfitLoss
-50457000
CY2022Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
29440000
CY2022Q2 fbio Tangible Assets Net
TangibleAssetsNet
334515000
CY2022Q2 us-gaap Assets
Assets
363955000
CY2021Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
12552000
CY2021Q4 fbio Tangible Assets Net
TangibleAssetsNet
383951000
CY2021Q4 us-gaap Assets
Assets
396503000
CY2022Q2 fbio Collaboration Revenue
CollaborationRevenue
577000
CY2021Q2 fbio Collaboration Revenue
CollaborationRevenue
2400000
fbio Collaboration Revenue
CollaborationRevenue
1154000
fbio Collaboration Revenue
CollaborationRevenue
3200000
CY2022Q2 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
18000
CY2021Q2 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
155000
us-gaap Revenue From Related Parties
RevenueFromRelatedParties
70000
us-gaap Revenue From Related Parties
RevenueFromRelatedParties
223000
CY2022Q2 us-gaap Other Income
OtherIncome
56000
us-gaap Other Income
OtherIncome
2556000
CY2022Q2 us-gaap Revenues
Revenues
18886000
CY2021Q2 us-gaap Revenues
Revenues
17843000
us-gaap Revenues
Revenues
42811000
us-gaap Revenues
Revenues
29430000
fbio Minimum Ownership Interest In Subsidiaries For Consolidated Income Tax Return
MinimumOwnershipInterestInSubsidiariesForConsolidatedIncomeTaxReturn
0.80
fbio Minimum Ownership Interest In Subsidiaries For Consolidated Income Tax Return
MinimumOwnershipInterestInSubsidiariesForConsolidatedIncomeTaxReturn
0.80
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0

Files In Submission

Name View Source Status
0001558370-22-013275-index-headers.html Edgar Link pending
0001558370-22-013275-index.html Edgar Link pending
0001558370-22-013275.txt Edgar Link pending
0001558370-22-013275-xbrl.zip Edgar Link pending
fbio-20220630.xsd Edgar Link pending
fbio-20220630x10q.htm Edgar Link pending
fbio-20220630xex31d1.htm Edgar Link pending
fbio-20220630xex31d2.htm Edgar Link pending
fbio-20220630xex32d1.htm Edgar Link pending
fbio-20220630xex32d2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
fbio-20220630_cal.xml Edgar Link unprocessable
fbio-20220630_def.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
fbio-20220630_lab.xml Edgar Link unprocessable
fbio-20220630x10q_htm.xml Edgar Link completed
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
fbio-20220630_pre.xml Edgar Link unprocessable